View clinical trials related to KSHV.
Filter by:Background: - KSHV inflammatory cytokine syndrome (KICS) is a newly recognized disease caused by Kaposi sarcoma-associated herpesvirus (KSHV). This virus can cause cancer. People with KICS can have severe symptoms. They include fever, weight loss, and fluid in the legs or abdomen. People with KICS may also be at risk of getting other cancers associated with KSHV. These cancers include Kaposi sarcoma and lymphoma. Because KICS is a newly identified disease, more information is needed on how the disease works and what can be done to treat it. Objectives: - To collect genetic and medical information from people with KSHV inflammatory cytokine syndrome. Eligibility: - Individuals at least 18 years of age who have Kaposi sarcoma herpes virus and symptoms that resemble those caused by KICS. Design: - Participants will have regular study visits. The schedule will be determined by the study researchers. - Participants will provide a complete medical history and have a full physical exam. Blood and urine samples will be collected as well. - People with KICS that requires treatment may get new experimental treatments. These treatments may include antiviral drugs and chemotherapy drugs, depending on the nature of the disease. - Participants will have imaging studies, such as chest x-rays and computed tomography scans, to study the tumors. - Bone marrow and lymph node biopsies may be done to collect tissue samples for study. - Participants who have Kaposi sarcoma will have photographs taken of their lesions.
Background: - Kaposi's sarcoma (KS) is a disease in which cancer cells are found in the tissues under the skin or mucous membranes that line the mouth, nose, and anus. KS causes red or purple patches (lesions) on the skin or mucous membranes and spreads to other organs in the body, such as the lungs, liver, or intestinal tract. - BAY 43-9006 inhibits the activity of several proteins or protein receptors in cells that are thought to be important to the progression of KS. Blocking these mechanisms may cause KS to get better. Objectives: - To learn about the toxicity and blood levels of BAY 43-9006 in people with KS who are and are not taking the anti-retroviral drug ritonavir. - To look for evidence of a beneficial treatment effect of BAY 43-9006 Eligibility: - Adults with confirmed KS, both HIV-positive and HIV-negative. - Patients must have either 1) at least five measurable KS lesions with no previous local therapy, or 2) other measurable non-skin disease that permits evaluation of a response to treatment. Design: - Patients are randomly assigned to a specific dose of BAY 43-9006. They take the drug by mouth either once or twice daily, depending on their dose group, for up to 54 weeks. - Drug blood levels are determined after patients have been taking BAY 43-9006 for 1 to 2 weeks by blood collections immediately before the dose and at 1, 2, 4, 8, 12, 16 and 24 hours after the dose. - Patients are evaluated every 3 weeks with review of a medication diary, interview about drug side effects, physical examination, and assessment of KS lesions. - KS lesions are photographed on entering the study and at other time points during the study. - CD4 cell counts and HIV viral load are tested every 12 weeks. - Biopsies are done at the start of the study, on day 15, and if it appears that all of the lesions have resolved. - Other procedures, such as CT or MRI scans, may be done if medically indicated.